Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Pulmocide Ltd.
Headquarters: London, United Kingdom
Website: http://www.pulmocide.com
Year Founded: 2013
Status: Private
BioCentury | Jun 8, 2023
Management Tracks
New CFO, commercial officer at Pulmocide
Plus: Helmling named CBO at eTheRNA, and updates from EpimAb, Ring, Amarna, XNK and more
BioCentury | Dec 6, 2022
Data Byte
Pulmocide joins trio of start-ups with venture raises
Entact Bio, Vega mark debuts alongside $52M series C extension for U.K.’s Pulmocide
BioCentury | Sep 20, 2021
Finance
Closing Europe’s largest biotech fund at $630M, Jeito readies to build portfolio
French VC gearing up to build portfolio of European companies focused on severe diseases in small patient populations
BioCentury | Jun 11, 2021
Finance
Investment in Pulmocide pushes Jeito portfolio into the clinic and beyond cell and gene therapy
Firm leads $92M in U.K. respiratory play
BioCentury | Mar 25, 2017
Finance
Respiratory redux
Pulmocide management, investor experience attracted SR One to lead $30.4M round
Items per page:
1 - 10 of 11